(Q38032249)

27 August 2017

title

Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis (English)

1 reference

Kailash Phatechand Bhatia

27 August 2017

1 reference

1 reference

series ordinal

3

object named as

Kailash Bhatia

1 reference

27 August 2017

Mark J Edwards

2

0 references

James T H Teo

series ordinal

1

object named as

James T Teo

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 August 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

27

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

1205-1215

1 reference

Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature

27 August 2017

cites work

1 reference

Is Tardive Dyskinesia a Drug Effect?

21 January 2018

1 reference

Tardive akathisia: an analysis of clinical features and response to open therapeutic trials

21 January 2018

1 reference

The natural history of tardive dystonia. A long-term follow-up study of 107 cases.

21 January 2018

1 reference

Tardive dystonia and severe tardive dyskinesia. A comparison of risk factors and prognosis

21 January 2018

1 reference

Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review

21 January 2018

1 reference

Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations

21 January 2018

1 reference

Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis

21 January 2018

1 reference

Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.

21 January 2018

1 reference

Observations on the effect of levodopa on tardive lingual-facial-buccal dyskinesia

21 January 2018

1 reference

Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission.

21 January 2018

1 reference

Current psychopathological theories of tardive dyskinesia and their implications for future research

21 January 2018

1 reference

Up-regulation of dopamine D2 receptor mRNA in rat striatum by chronic neuroleptic treatment

21 January 2018

1 reference

The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats

21 January 2018

1 reference

Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study

21 January 2018

1 reference

Amphetamine-induced dopamine release and post-synaptic specific binding in patients with mild tardive dyskinesia

21 January 2018

1 reference

Striatal dopamine D2 receptors in tardive dyskinesia: PET study

21 January 2018

1 reference

Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?

21 January 2018

1 reference

Effects of age on reserpine-induced orofacial dyskinesia and possible protection of diphenyl diselenide.

21 January 2018

1 reference

Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia

21 January 2018

1 reference

Oxidative mechanisms and tardive dyskinesia

21 January 2018

1 reference

Iron, akathisia, and antipsychotic drugs.

21 January 2018

1 reference

Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain

21 January 2018

1 reference

Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.

21 January 2018

1 reference

Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group.

21 January 2018

1 reference

Coenzyme Q10 does not prevent oral dyskinesias induced by long-term haloperidol treatment of rats

21 January 2018

1 reference

Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial.

21 January 2018

1 reference

Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment.

21 January 2018

1 reference

Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia

21 January 2018

1 reference

An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone

21 January 2018

1 reference

Neural damage in the lenticular nucleus linked with tardive dyskinesia in schizophrenia: a preliminary study using proton magnetic resonance spectroscopy

21 January 2018

1 reference

The relationship between oral dyskinesias produced by long-term haloperidol treatment, the density of striatal preproenkephalin messenger RNA and enkephalin peptide, and the number of striatal neurons expressing preproenkephalin messenger RNA in rat

21 January 2018

1 reference

Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction

21 January 2018

1 reference

GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study

21 January 2018

1 reference

Feedforward inhibition of projection neurons by fast-spiking GABA interneurons in the rat striatum in vivo.

21 January 2018

1 reference

Distinct roles of GABAergic interneurons in the regulation of striatal output pathways

21 January 2018

1 reference

Selective activation of striatal fast-spiking interneurons during choice execution

21 January 2018

1 reference

Selective inhibition of striatal fast-spiking interneurons causes dyskinesias

21 January 2018

1 reference

Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?

21 January 2018

1 reference

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

21 January 2018

1 reference

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

21 January 2018

1 reference

Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients

21 January 2018

1 reference

The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia

21 January 2018

1 reference

Extrapyramidal side-effects of antipsychotics in a randomised trial

21 January 2018

1 reference

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study

21 January 2018

1 reference

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

Second-generation antipsychotics for schizophrenia: can we resolve the conflict?

21 January 2018

1 reference

Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.

21 January 2018

1 reference

Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study

21 January 2018

1 reference

Tardive dyskinesia: eliminated, forgotten, or overshadowed?

21 January 2018

1 reference

Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum

21 January 2018

1 reference

Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models

21 January 2018

1 reference

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

21 January 2018

1 reference

Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis

21 January 2018

1 reference

Tardive dyskinesia and other movement disorders secondary to aripiprazole

21 January 2018

1 reference

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

21 January 2018

1 reference

Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions

21 January 2018

1 reference

Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.

21 January 2018

1 reference

Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

21 January 2018

1 reference

Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

21 January 2018

1 reference

Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism

21 January 2018

1 reference

Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis

21 January 2018

1 reference

Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia

21 January 2018

1 reference

Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia.

21 January 2018

1 reference

Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients

21 January 2018

1 reference

Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms

21 January 2018

1 reference

Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia

21 January 2018

1 reference

Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor

21 January 2018

1 reference

Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia

21 January 2018

1 reference

Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype

21 January 2018

1 reference

The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX.

21 January 2018

1 reference

Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility.

21 January 2018

1 reference

Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients

21 January 2018

1 reference

Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia

21 January 2018

1 reference

Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients

21 January 2018

1 reference

BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population

21 January 2018

1 reference

Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia.

21 January 2018

1 reference

Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients

21 January 2018

1 reference

Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia

21 January 2018

1 reference

Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan

21 January 2018

1 reference

Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness

21 January 2018

1 reference

Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians

21 January 2018

1 reference

Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia

21 January 2018

1 reference

Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia

21 January 2018

1 reference

The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia

21 January 2018

1 reference

Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics.

21 January 2018

1 reference

Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice

21 January 2018

1 reference

Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path

21 January 2018

1 reference

21 January 2018

1 reference

Striatal plasticity and basal ganglia circuit function

21 January 2018

1 reference

Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum

21 January 2018

1 reference

Dopamine-mediated regulation of corticostriatal synaptic plasticity.

21 January 2018

1 reference

Transcranial magnetic stimulation: from neurophysiology to pharmacology, molecular biology and genomics.

21 January 2018

1 reference

Abnormal bidirectional plasticity-like effects in Parkinson's disease.

21 January 2018

1 reference

Boosting focally-induced brain plasticity by dopamine

21 January 2018

1 reference

Dosage-dependent non-linear effect of L-dopa on human motor cortex plasticity.

21 January 2018

1 reference

Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.

21 January 2018

1 reference

Dopaminergic modulation of long-lasting direct current-induced cortical excitability changes in the human motor cortex.

21 January 2018

1 reference

Differing effects of intracortical circuits on plasticity.

21 January 2018

1 reference

The facilitatory effects of intermittent theta burst stimulation on corticospinal excitability are enhanced by nicotine

21 January 2018

1 reference

Neuromodulatory neurotransmitters influence LTP-like plasticity in human cortex: a pharmaco-TMS study

21 January 2018

1 reference

D1-receptor impact on neuroplasticity in humans

21 January 2018

1 reference

D2 receptor block abolishes θ burst stimulation-induced neuroplasticity in the human motor cortex

21 January 2018

1 reference

Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors.

21 January 2018

1 reference

Plastic abnormalities in experimental Huntington's disease

21 January 2018

1 reference

Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons

21 January 2018

1 reference

Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment

21 January 2018

1 reference

Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.

21 January 2018

1 reference

Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.

21 January 2018

1 reference

Consensus paper: use of transcranial magnetic stimulation to probe motor cortex plasticity in dystonia and levodopa-induced dyskinesia.

21 January 2018

1 reference

Abnormal motor cortex plasticity in premanifest and very early manifest Huntington disease

21 January 2018

1 reference

Abnormal cortical and brain stem plasticity in Gilles de la Tourette syndrome.

21 January 2018

1 reference

Abnormalities in motor cortical plasticity differentiate manifesting and nonmanifesting DYT1 carriers.

21 January 2018

1 reference

Convergent evidence for abnormal striatal synaptic plasticity in dystonia

21 January 2018

1 reference

Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia

21 January 2018

1 reference

Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases

21 January 2018

1 reference

Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia

21 January 2018

1 reference

Sensorimotor integration in movement disorders

21 January 2018

1 reference

Homeostatic-like plasticity of the primary motor hand area is impaired in focal hand dystonia.

21 January 2018

1 reference

Task-specific hand dystonia: can too much plasticity be bad for you?

21 January 2018

1 reference

Abnormal plasticity in dystonia: Disruption of synaptic homeostasis

21 January 2018

1 reference

Abnormal motor unit synchronization of antagonist muscles underlies pathological co-contraction in upper limb dystonia.

21 January 2018

1 reference

Not all that moves is tardive dyskinesia

21 January 2018

1 reference

Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis

21 January 2018

1 reference

Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.

21 January 2018

1 reference

Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology

21 January 2018

1 reference

The motor disorders of severe psychiatric illness: a conflict of paradigms.

21 January 2018

1 reference

DSM-IV catatonia signs and criteria in first-episode, drug-naive, psychotic patients: psychometric validity and response to antipsychotic medication

21 January 2018

1 reference

The structural brain correlates of neurological soft signs in healthy individuals.

21 January 2018

1 reference

The structural brain correlates of neurological soft signs in AESOP first-episode psychoses study

21 January 2018

1 reference

Clinical rating scales and instruments: how do they compare in assessing abnormal, involuntary movements?

21 January 2018

1 reference

A critical review of rating scales in the assessment of movement disorders in schizophrenia

21 January 2018

1 reference

Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and Cortex

21 January 2018

1 reference

Foot, hand, face and eye representation in the human striatum.

21 January 2018

1 reference

Elevated striatal dopamine function linked to prodromal signs of schizophrenia

21 January 2018

1 reference

Increased synaptic dopamine function in associative regions of the striatum in schizophrenia

21 January 2018

1 reference

Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis

21 January 2018

1 reference

Increased intrinsic brain activity in the striatum reflects symptom dimensions in schizophrenia

21 January 2018

1 reference

Impaired NMDA receptor transmission alters striatal synapses and DISC1 protein in an age-dependent manner.

21 January 2018

1 reference

21 January 2018

1 reference

Differential effect of aging on synaptic plasticity in the ventral and dorsal striatum

21 January 2018

1 reference

Effects of aging on the human motor cortical plasticity studied by paired associative stimulation

21 January 2018

1 reference

Is schizophrenia a neurodevelopmental disorder?

21 January 2018

1 reference

Neurodevelopmental hypothesis of schizophrenia

21 January 2018

1 reference

De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia.

21 January 2018

1 reference

Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia

21 January 2018

1 reference

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

The NMDA antagonist model for schizophrenia: promise and pitfalls.

21 January 2018

1 reference

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

21 January 2018

1 reference

Bringing order to the glutamate chaos in schizophrenia

21 January 2018

1 reference

Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors.

21 January 2018

1 reference

Plasticity in human motor cortex is in part genetically determined.

21 January 2018

1 reference

Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes

21 January 2018

1 reference

Chronic deep brain stimulation in patients with tardive dystonia without a history of major psychosis

21 January 2018

1 reference

Deep brain stimulation of the internal globus pallidus for refractory tardive dystonia.

21 January 2018

1 reference

Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia

21 January 2018

1 reference

Long-term high-frequency bilateral pallidal stimulation for neuroleptic-induced tardive dystonia. Report of two cases.

21 January 2018

1 reference

Long-term effects of pallidal deep brain stimulation in tardive dystonia.

21 January 2018

1 reference

A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation.

21 January 2018

1 reference

Bilateral deep brain stimulation of the globus pallidus internus in tardive dystonia

21 January 2018

1 reference

Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia.

21 January 2018

1 reference

Treatment of severe tardive dystonia with pallidal deep brain stimulation.

21 January 2018

1 reference

Shaping reversibility? Long-term deep brain stimulation in dystonia: the relationship between effects on electrophysiology and clinical symptoms.

21 January 2018

1 reference

Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats

21 January 2018

1 reference

Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia

21 January 2018

1 reference

Studying synaptic plasticity in the human brain and opportunities for drug discovery

21 January 2018

1 reference

Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients

21 January 2018

1 reference

The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia

21 January 2018

1 reference

Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.25107

1 reference

27 August 2017

1 reference